TakahiroIgnacioNakamuraMD

PubMed

• 15 citations
  Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.
  Jordan E Axelrad, Terry Li, Salam P Bachour, Takahiro I Nakamura, Ravi Shah, Michael C Sachs, Shannon Chang, David P Hudesman, Stefan D Holubar, Amy L Lightner, Edward...> ;Inflammatory Bowel Diseases. 2023 Jun 1
• 7 citations
  Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's Disease.
  Bachour, S., Shah, R., Lyu, R., Nakamura, T., Shen, M., Li, T., Dane, B., Barnes, E., Rieder, F., Cohen, B., Qazi, T., Lashner, B., Achkar, J., Philpott, J., Holubar, ...> ;Clinical Gastroenterology and Hepatology. 2022 Oct 1
• 13 citations
  Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study.
  Jingzhou Wang, Takahiro I. Nakamura, Anne G. Tuskey, Brian W. Behm> ;Intestinal Research. 2019 Oct 14

Journal Articles

• Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study  
  Wang J, Nakamura TI, Tuskey A, Behm B, Intestinal Research, 10/14/2019

Abstracts/Posters

• Tumor necrosis factor antagonists are superior to ustekinumab and vedolizumab for the prevention of postoperative recurrence in adult Crohn’s disease.
  Nakamura TI, Main M, Chang S, Click B, Hudesman DP, Axelrad JE., 2019 American College of Gastroenterology Annual Meeting, San Antonio, TX, 10/27/2019
• Polypharmacy and drug-drug interactions among patients with ulcerative colitis
  Figueroa E, Overby M, Behm B, Nakamura T, Wentworth B, American Journal of Gastroenterology, 114: S25-S26, 7/2019
• RISK FACTORS FOR NON-ADHERENCE TO BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE
  Brian J. Wentworth, Ross C.D. Buerlein, Takahiro I. Nakamura, Anne G. Tuskey, M. Ashely Overby, Mark E. Smolkin, Brian W. Behm, Gastroenterology, 1/2018